OMB157G

Drug Novartis Pharma AG
Total Payments
$225,881
Transactions
103
Doctors
13
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2018 $95,893 58 10
2017 $129,988 45 8

Payments by Nature

Nature of Payment Amount Transactions Share
Travel and Lodging $118,800 55 52.6%
Consulting Fee $104,759 13 46.4%
Food and Beverage $2,321 35 1.0%

Top Doctors Receiving Payments for OMB157G

Doctor Specialty Location Total Records
, M.D Neurology Houston, TX $85,467 51
Amit Bar-Or Neurology Philadelphia, PA $34,004 11
, MD Pediatric Pulmonology Pittsburgh, PA $28,022 1
, M.D Neurology San Francisco, CA $18,589 5
, M.D Psychiatry Dallas, TX $13,809 6
, MD Neurology Boston, MA $13,513 6
, M.D Neurology Scottsdale, AZ $12,135 5
, M.D Neurology Boston, MA $12,041 6
, MD Neurology Saint Louis, MO $7,996 5
, M.D Internal Medicine San Francisco, CA $96.65 2
, M.D Neurology East Setauket, NY $96.65 2
, MD Neurology Saint Louis, MO $96.65 2
, D.O Neurology Kansas City, KS $13.00 1

About OMB157G

OMB157G is a drug associated with $225,881 in payments to 13 healthcare providers, recorded across 103 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.

Payment data is available from 2017 to 2018. In 2018, $95,893 was paid across 58 transactions to 10 doctors.

The most common payment nature for OMB157G is "Travel and Lodging" ($118,800, 52.6% of total).